Rivastigmine for dementia associated with Parkinson's disease
Tarih
2004Yazar
Wolters, E
Lane, R
Rosa, MM
Quarg, P
Tekin, S
Emre, M
Aarsland, D
Albanese, A
Byrne, EJ
Deuschl, G
De Deyn, PP
Durif, F
Kulisevsky, J
van Laar, T
Lees, A
Poewe, W
Robillard, A
Üst veri
Tüm öğe kaydını gösterÖzet
Background: Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients.
Koleksiyonlar
- Makale [92796]